Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Secondary bacterial pneumonia is an important cause of influenza-associated death. Although antibacterial therapy is standard, antiviral therapy has been ignored because viral infections usually resolve by the time bacterial pneumonia presents. In the present study, antiviral compounds were tested in a mouse model of secondary pneumococcal pneumonia after influenza. Treatment with oseltamivir improved survival in mice from 0% to 75%, even when therapy was delayed for up to 5 days after infection with influenza virus. In mice, treatment with rimantadine had no effect on survival. Treatment with ampicillin cleared infection but, in the absence of treatment with oseltamivir, did not improve survival. Pneumonia developed in only 7 of the 22 mice receiving oseltamivir, and subsequent treatment with ampicillin resulted in cure (100% survival). Treatment of the predisposing influenza-virus infection with inhibitors specific for the viral neuraminidase may improve the efficacy of antibiotics and increase survival in persons who are at high risk for complications and mortality during influenza.

Original languageEnglish (US)
Pages (from-to)519-526
Number of pages8
JournalJournal of Infectious Diseases
Volume190
Issue number3
DOIs
StatePublished - Aug 1 2004
Externally publishedYes

Fingerprint

Bacterial Pneumonia
Human Influenza
Antiviral Agents
Oseltamivir
Survival
Virus Diseases
Ampicillin
Orthomyxoviridae
Rimantadine
Pneumococcal Pneumonia
Neuraminidase
Infection
Pneumonia
Therapeutics
Anti-Bacterial Agents
Mortality

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza. / Mccullers, Jonathan.

In: Journal of Infectious Diseases, Vol. 190, No. 3, 01.08.2004, p. 519-526.

Research output: Contribution to journalArticle

@article{3af0161702e24cabaa8d0028060c6b71,
title = "Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza",
abstract = "Secondary bacterial pneumonia is an important cause of influenza-associated death. Although antibacterial therapy is standard, antiviral therapy has been ignored because viral infections usually resolve by the time bacterial pneumonia presents. In the present study, antiviral compounds were tested in a mouse model of secondary pneumococcal pneumonia after influenza. Treatment with oseltamivir improved survival in mice from 0{\%} to 75{\%}, even when therapy was delayed for up to 5 days after infection with influenza virus. In mice, treatment with rimantadine had no effect on survival. Treatment with ampicillin cleared infection but, in the absence of treatment with oseltamivir, did not improve survival. Pneumonia developed in only 7 of the 22 mice receiving oseltamivir, and subsequent treatment with ampicillin resulted in cure (100{\%} survival). Treatment of the predisposing influenza-virus infection with inhibitors specific for the viral neuraminidase may improve the efficacy of antibiotics and increase survival in persons who are at high risk for complications and mortality during influenza.",
author = "Jonathan Mccullers",
year = "2004",
month = "8",
day = "1",
doi = "10.1086/421525",
language = "English (US)",
volume = "190",
pages = "519--526",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza

AU - Mccullers, Jonathan

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Secondary bacterial pneumonia is an important cause of influenza-associated death. Although antibacterial therapy is standard, antiviral therapy has been ignored because viral infections usually resolve by the time bacterial pneumonia presents. In the present study, antiviral compounds were tested in a mouse model of secondary pneumococcal pneumonia after influenza. Treatment with oseltamivir improved survival in mice from 0% to 75%, even when therapy was delayed for up to 5 days after infection with influenza virus. In mice, treatment with rimantadine had no effect on survival. Treatment with ampicillin cleared infection but, in the absence of treatment with oseltamivir, did not improve survival. Pneumonia developed in only 7 of the 22 mice receiving oseltamivir, and subsequent treatment with ampicillin resulted in cure (100% survival). Treatment of the predisposing influenza-virus infection with inhibitors specific for the viral neuraminidase may improve the efficacy of antibiotics and increase survival in persons who are at high risk for complications and mortality during influenza.

AB - Secondary bacterial pneumonia is an important cause of influenza-associated death. Although antibacterial therapy is standard, antiviral therapy has been ignored because viral infections usually resolve by the time bacterial pneumonia presents. In the present study, antiviral compounds were tested in a mouse model of secondary pneumococcal pneumonia after influenza. Treatment with oseltamivir improved survival in mice from 0% to 75%, even when therapy was delayed for up to 5 days after infection with influenza virus. In mice, treatment with rimantadine had no effect on survival. Treatment with ampicillin cleared infection but, in the absence of treatment with oseltamivir, did not improve survival. Pneumonia developed in only 7 of the 22 mice receiving oseltamivir, and subsequent treatment with ampicillin resulted in cure (100% survival). Treatment of the predisposing influenza-virus infection with inhibitors specific for the viral neuraminidase may improve the efficacy of antibiotics and increase survival in persons who are at high risk for complications and mortality during influenza.

UR - http://www.scopus.com/inward/record.url?scp=3242812828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242812828&partnerID=8YFLogxK

U2 - 10.1086/421525

DO - 10.1086/421525

M3 - Article

VL - 190

SP - 519

EP - 526

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 3

ER -